1700022C21Rik Activators
ZNRD1-AS1 Activators encompass a range of chemical compounds that, through their influence on various cellular signaling pathways, may indirectly enhance the functional activity of the uncharacterized protein ZNRD1-AS1. Compounds such as Forskolin and Rolipram work by increasing intracellular cAMP levels, which subsequently enhance protein kinase A (PKA) activity, possibly affecting substrates that interact with ZNRD1-AS1, thereby leading to its functional activation. Similarly, Ionomycin and BAPTA-AM modulate intracellular calcium levels, which could activate calcium-dependent protein kinases, potentially influencing ZNRD1-AS1's activity. TheGiven the nature of ZNRD1-AS1 as a putative uncharacterized protein, direct activators may not have been well-characterized. Nonetheless, based on the known signaling pathways and logical analysis, I'll provide a list of chemical compounds that could potentially act as indirect activators.
Since ZNRD1-AS1 is uncharacterized, its role in specific signaling pathways is speculative. ZNRD1-AS1 Activators encompass a range of chemical compounds that, through their influence on various cellular signaling pathways, may indirectly enhance the functional activity of the uncharacterized protein ZNRD1-AS1. Compounds such as Forskolin and Rolipram work by increasing intracellular cAMP levels, which subsequently enhance protein kinase A (PKA) activity, possibly affecting substrates that interact with ZNRD1-AS1, thereby leading to its functional activation. Similarly, Ionomycin and BAPTA-AM modulate intracellular calcium levels, which could activate calcium-dependent protein kinases, potentially influencing ZNRD1-AS1's activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram inhibits phosphodiesterase 4, leading to increased cAMP levels, which can indirectly lead to activation of ZNRD1-AS1 through PKA-dependent signaling pathways. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin acts as a calcium ionophore, increasing intracellular calcium levels, which might activate calcium-dependent protein kinases that could phosphorylate ZNRD1-AS1 or associated proteins, enhancing its activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a PKC activator that can phosphorylate substrates that could interact with ZNRD1-AS1, potentially enhancing its activity through PKC-dependent signaling pathways. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
SB216763 is a GSK-3 inhibitor, which can lead to the disinhibition of downstream proteins in the Wnt signaling pathway, potentially affecting the functionality of ZNRD1-AS1. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that could lead to alterations in the AKT signaling pathway, potentially resulting in the activation of downstream proteins that may interact with ZNRD1-AS1. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which may have downstream effects on cellular growth and survival pathways that could include ZNRD1-AS1 activation indirectly. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an MEK inhibitor that could affect MAPK/ERK pathway signaling, potentially leading to alterations in phosphorylation patterns that could indirectly enhance the activity of ZNRD1-AS1. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, which may result in changes in AP-1 transcription factor activity, potentially affecting the functional state of ZNRD1-AS1. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
BAPTA-AM is a cell-permeable calcium chelator, which by modulating calcium signaling could influence downstream kinases that may activate ZNRD1-AS1. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
KN-93 is an inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMKII), which could modulate downstream signaling pathways potentially involved in ZNRD1-AS1 activation. | ||||||